Despite the developing knowledge in understanding the role of insulin pathways in dyslipidemia, to date no study has considered whether this mechanism works the same in all participants; and whether minor alleles are more likely to be risk alleles in IR mechanisms in metabolic diseases or not. The gene discussed is INS; the disease is metabolic disease.